Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal ...

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The ...

CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Breyanzi (lisocabtagene maraleucel), ...

Unaddressed adverse effects, such as fatigue, significantly reduce patient confidence in care plans and negatively impact quality of life for individuals with lymphoma and chronic lymphocytic leukemia ...

The U.S. Food and Drug Administration (FDA) has approved Brukinsa (zanubrutinib) for the treatment of the blood and bone cancers known as chronic lymphocytic leukemia (CLL) and small lymphocytic ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The indication applies to use of the agent in adults ...

—The subtype of lymphoma and the timing of anticancer treatment was shown to directly affect the level of seroconversion in cancer patients administered COVID vaccination. Reviewed by Catherine E. Lai ...